Konstantinos Leventakos

Feb 15, 2024 | acsjournals.onlinelibrary.wiley.com | Aakash Desai |Caleb Smith |Joshua C. Pritchett |Konstantinos Leventakos

INTRODUCTION The advent of immune checkpoint inhibitor (ICI) therapy was initially shown to offer a significant overall survival (OS) benefit compared with docetaxel-based chemotherapy in chemotherapy-pretreated patients,1, 2 which led to Food and Drug Administration (FDA) approval by late 2015 as second-line or later treatment in patients with advanced non–small cell lung cancer (NSCLC).